CastleKnight Management LP Sells 413,900 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

CastleKnight Management LP lessened its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 62.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 245,200 shares of the company’s stock after selling 413,900 shares during the period. CastleKnight Management LP’s holdings in Teva Pharmaceutical Industries were worth $7,653,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Global Retirement Partners LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 27.3% during the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock valued at $42,000 after purchasing an additional 292 shares during the last quarter. Captrust Financial Advisors boosted its holdings in shares of Teva Pharmaceutical Industries by 2.1% during the 4th quarter. Captrust Financial Advisors now owns 14,715 shares of the company’s stock valued at $459,000 after purchasing an additional 302 shares during the last quarter. Banque Cantonale Vaudoise boosted its holdings in shares of Teva Pharmaceutical Industries by 6.3% during the 4th quarter. Banque Cantonale Vaudoise now owns 5,133 shares of the company’s stock valued at $160,000 after purchasing an additional 306 shares during the last quarter. Ethic Inc. boosted its holdings in shares of Teva Pharmaceutical Industries by 1.8% during the 4th quarter. Ethic Inc. now owns 18,127 shares of the company’s stock valued at $566,000 after purchasing an additional 325 shares during the last quarter. Finally, Allworth Financial LP boosted its holdings in shares of Teva Pharmaceutical Industries by 53.8% during the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after purchasing an additional 329 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Down 1.0%

Shares of NYSE TEVA opened at $32.59 on Thursday. The firm’s 50-day moving average price is $33.46 and its 200-day moving average price is $32.17. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70. The stock has a market capitalization of $37.47 billion, a price-to-earnings ratio of 24.50, a P/E/G ratio of 3.36 and a beta of 0.84. Teva Pharmaceutical Industries Ltd. has a 12-month low of $14.99 and a 12-month high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. The firm had revenue of $3.98 billion for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. On average, equities research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

TEVA has been the subject of several research reports. Truist Financial increased their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Piper Sandler reissued an “overweight” rating and set a $42.00 price objective (up from $41.00) on shares of Teva Pharmaceutical Industries in a report on Thursday, April 30th. UBS Group increased their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Bank of America increased their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, April 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Monday, April 20th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and a consensus price target of $41.78.

Insider Activity

In other news, EVP Richard Daniell sold 30,000 shares of the company’s stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $35.40, for a total transaction of $1,062,000.00. Following the sale, the executive vice president directly owned 55,755 shares in the company, valued at approximately $1,973,727. This represents a 34.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Christine Fox sold 21,258 shares of the company’s stock in a transaction dated Thursday, April 30th. The shares were sold at an average price of $35.31, for a total transaction of $750,619.98. Following the sale, the executive vice president owned 63,647 shares in the company, valued at $2,247,375.57. This represents a 25.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 465,931 shares of company stock worth $16,332,989. 0.54% of the stock is owned by insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.